{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:17:12Z","timestamp":1760984232383},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.vaccine.2011.11.051","type":"journal-article","created":{"date-parts":[[2011,11,20]],"date-time":"2011-11-20T19:57:28Z","timestamp":1321819048000},"page":"774-783","source":"Crossref","is-referenced-by-count":24,"title":["A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix\u00ae in subjects aged 11\u201317 years: An open, randomised, controlled trial"],"prefix":"10.1016","volume":"30","author":[{"given":"Lars","family":"\u00d8stergaard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven-Arne","family":"Silfverdal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Berglund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl-Erik","family":"Flodmark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronique","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaela","family":"Baine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2011.11.051_bib0005","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1586\/14760584.6.4.485","article-title":"Neisseria vaccines 2007","volume":"6","author":"Findlow","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0010","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1001\/jama.286.6.694","article-title":"Invasive meningococcal disease in adolescents and young adults","volume":"286","author":"Harrison","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0015","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0020","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","article-title":"Meningococcal disease","volume":"344","author":"Rosenstein","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0025","unstructured":"The European Union Invasive Bacterial Infections Surveillance Network. Neisseria meningitidis network (in collaboration with EU-MenNet) [updated 2008 June 17; cited 2010 November 4]. Available from: http:\/\/www.euibis.org\/neisseria.htm."},{"key":"10.1016\/j.vaccine.2011.11.051_bib0030","unstructured":"Centers for Disease Control and Prevention. Meningitis in other countries [updated 2009 December 8; cited 2010 December 20]. Available from: http:\/\/www.cdc.gov\/meningitis\/global.html."},{"key":"10.1016\/j.vaccine.2011.11.051_bib0035","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/14760584.5.6.851","article-title":"Long-term protection in children with meningococcal C conjugate vaccination: lessons learned","volume":"5","author":"Borrow","year":"2006","journal-title":"Expert Rev Vaccines"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2011.11.051_bib0040","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1086\/648966","article-title":"Review of meningococcal group B vaccines","volume":"50","author":"Granoff","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0045","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(02)08416-7","article-title":"Development of vaccines against meningococcal disease","volume":"359","author":"Jodar","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0050","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0055","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1128\/CMR.19.1.142-164.2006","article-title":"Prospects for vaccine prevention of meningococcal infection","volume":"19","author":"Harrison","year":"2006","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0060","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1136\/bmj.39563.545255.AE","article-title":"Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study","volume":"336","author":"Snape","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0065","first-page":"794","article-title":"Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11\u201318 years with meningococcal conjugate vaccine","volume":"56","author":"Centers for Disease Control and Prevention","year":"2007","journal-title":"Morb Mortal Wkly Rep"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2011.11.051_bib0070","doi-asserted-by":"crossref","first-page":"B30","DOI":"10.1016\/j.vaccine.2009.05.003","article-title":"Quadrivalent meningococcal conjugate vaccines","volume":"27","author":"Pace","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0075","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/01.inf.0000126297.28952.f8","article-title":"Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants","volume":"23","author":"Rennels","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0080","first-page":"72","article-title":"Updated recommendations for use of meningococcal conjugate vaccines-Advisory Committee on Immunization Practices (ACIP), 2010","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0085","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.vaccine.2009.10.064","article-title":"A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children","volume":"28","author":"Knuf","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0090","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.vaccine.2008.08.075","article-title":"Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15\u201325 years","volume":"27","author":"\u00d8stergaard","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0095","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4161\/hv.7.2.14068","article-title":"Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults","volume":"7","author":"Bermal","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0100","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/INF.0b013e3182054ab9","article-title":"Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10\u201325 years of age","volume":"30","author":"Baxter","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0105","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/INF.0b013e31820e6e02","article-title":"Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine administered to 2\u201310 year olds is non-inferior to a licensed ACWY polysaccharide vaccine, with an acceptable safety profile","volume":"30","author":"Memish","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0110","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1016\/j.vaccine.2011.03.043","article-title":"Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles\u2013mumps\u2013rubella\u2013varicella vaccine during the second year of life: An open, randomized controlled","volume":"29","author":"Vesikari","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0115","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1016\/j.vaccine.2011.03.009","article-title":"An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix\u2122 hexa is immunogenic, with an acceptable safety profile in 12\u201323-month-old children","volume":"29","author":"Knuf","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0120","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1016\/S0264-410X(00)00464-3","article-title":"Combining hepatitis A and B vaccination in children and adolescents","volume":"19","author":"Van Damme","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0125","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1586\/14760584.3.3.249","article-title":"A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine","volume":"3","author":"Van Damme","year":"2004","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0130","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1001\/jama.293.14.1751","article-title":"Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial","volume":"293","author":"Buttery","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0135","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1016\/j.vaccine.2010.06.026","article-title":"Glycoconjugate vaccines and immune interference: a review","volume":"28","author":"Dagan","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0140","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/adc.2005.076109","article-title":"Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age","volume":"92","author":"Kitchin","year":"2007","journal-title":"Arch Dis Child"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2011.11.051_bib0145","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.jcpa.2007.04.014","article-title":"The nature and consequences of intra- and inter-vaccine interference","volume":"137","author":"Vidor","year":"2007","journal-title":"J Comp Pathol"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0150","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CDLI.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0155","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection \u2013 serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0160","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/CDLI.10.5.780-786.2003","article-title":"Validation of serological correlate of protection for meningococcal c conjugate vaccine by using efficacy estimates from postlicensure surveillance in England","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0165","first-page":"1016","article-title":"Inadvertent misadministration of meningococcal conjugate vaccine-United States, June\u2013August 2005","volume":"55","author":"Centers for Disease Control and Prevention","year":"2006","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0170","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/IAI.69.3.1568-1573.2001","article-title":"Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection","volume":"69","author":"Borrow","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0175","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1128\/JCM.32.6.1475-1482.1994","article-title":"Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay","volume":"32","author":"Gheesling","year":"1994","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0180","first-page":"149","article-title":"Serologic response to serogroup C meningococcal vaccine in Brazilian preschool children","volume":"16","author":"Amato Neto","year":"1974","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0185","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0092-1157(83)80038-9","article-title":"A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera","volume":"11","author":"Melville-Smith","year":"1983","journal-title":"J Biol Stand"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0190","first-page":"1","article-title":"Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"55","author":"Fiore","year":"2006","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0195","first-page":"1","article-title":"A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults","volume":"55","author":"Mast","year":"2006","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0200","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1128\/CDLI.8.3.616-623.2001","article-title":"Importance of complement source in measuring meningococcal bactericidal titers","volume":"8","author":"Santos","year":"2001","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0205","doi-asserted-by":"crossref","unstructured":"Ostergaard LJ, Bianco V, Van der Wielen M, Miller J. Persistence of immune response to candidate meningococcal serogroups A,C,W-135,Y tetanus toxoid-conjugated vaccine (MenACWY-TT) up to 42 months following primary vaccination. In: European academy of paediatric societies \u2013 3rd congress; 2010 [Abstract no. 543].","DOI":"10.1203\/00006450-201011001-00530"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0210","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1086\/599117","article-title":"Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents","volume":"49","author":"Jackson","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0215","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/INF.0b013e31818a0237","article-title":"A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents","volume":"28","author":"Jackson","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0220","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/archpedi.159.10.907","article-title":"Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents","volume":"159","author":"Keyserling","year":"2005","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.vaccine.2011.11.051_bib0225","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.vaccine.2009.10.104","article-title":"Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age","volume":"28","author":"Black","year":"2010","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11018366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11018366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T19:51:34Z","timestamp":1593287494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11018366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0264410X11018366"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.11.051","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}